Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26670917 | 0.76 | GRIN2B (0.38) | GRIN1GRIN2B | |
| SCHEMBL23756211 | 0.75 | ALDH1A1 (0.43) | TP53KMT2AALDH1A1POLBMAPT | |
| SCHEMBL29942035 | 0.75 | ALDH1A1 (0.43) | TP53KMT2AALDH1A1POLBMAPT | |
| SCHEMBL26670793 | 0.75 | GRIN2B (0.40) | GRIN1GRIN2B | |
| SCHEMBL26660771 | 0.74 | NOD2 (0.45) | TP53KMT2ANOD2NOD1MAPT | |
| SCHEMBL16473015 | 0.74 | NOD2 (0.55) | TP53KMT2ANOD2NOD1ALDH1A1 | |
| SCHEMBL21683342 | 0.74 | NOD2 (0.44) | TP53KMT2ANOD2NOD1MAPT | |
| SCHEMBL29941899 | 0.74 | NOD2 (0.44) | TP53KMT2ANOD2NOD1MAPT | |
| SCHEMBL21295051 | 0.73 | TSHR (0.44) | TP53KMT2ANOD2NOD1ALDH1A1 | |
| SCHEMBL29641140 | 0.73 | MAPT (0.43) | TP53KMT2ANOD2NOD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| EP-4531849-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119604287-A | Heterocyclic PAD4 inhibitors | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2023230609-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230609-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI6, PADI2 | TP53 1218/4885KMT2A 488/4885NOD2 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.